219 related articles for article (PubMed ID: 27990590)
1. Angiopoietins as serum biomarkers for lymphatic anomalies.
Le Cras TD; Mobberley-Schuman PS; Broering M; Fei L; Trenor CC; Adams DM
Angiogenesis; 2017 Feb; 20(1):163-173. PubMed ID: 27990590
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
3. Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity.
Allen-Rhoades W; Al-Ibraheemi A; Kohorst M; Tollefson M; Hull N; Polites S; Folpe AL
Hum Pathol; 2022 Apr; 122():72-81. PubMed ID: 35202617
[TBL] [Abstract][Full Text] [Related]
4. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of kaposiform lymphangiomatosis with sirolimus.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Jul; 62(7):1291-3. PubMed ID: 25598153
[TBL] [Abstract][Full Text] [Related]
6. Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.
Ji Y; Chen S; Peng S; Xia C; Li L
Orphanet J Rare Dis; 2019 Jul; 14(1):165. PubMed ID: 31277673
[TBL] [Abstract][Full Text] [Related]
7. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.
Croteau SE; Kozakewich HP; Perez-Atayde AR; Fishman SJ; Alomari AI; Chaudry G; Mulliken JB; Trenor CC
J Pediatr; 2014 Feb; 164(2):383-8. PubMed ID: 24252784
[TBL] [Abstract][Full Text] [Related]
8. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals.
Croteau SE; Liang MG; Kozakewich HP; Alomari AI; Fishman SJ; Mulliken JB; Trenor CC
J Pediatr; 2013 Jan; 162(1):142-7. PubMed ID: 22871490
[TBL] [Abstract][Full Text] [Related]
9. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options.
Schmid I; Klenk AK; Sparber-Sauer M; Koscielniak E; Maxwell R; Häberle B
World J Pediatr; 2018 Aug; 14(4):322-329. PubMed ID: 30054848
[TBL] [Abstract][Full Text] [Related]
10. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angioma.
Gong X; Ying H; Zhang Z; Wang L; Li J; Ding A; Zhou L; Lin X; Xiong P
J Dermatol; 2019 Oct; 46(10):835-842. PubMed ID: 31373042
[TBL] [Abstract][Full Text] [Related]
12. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon in an infant girl.
Helligsø L; Mikkelsen TS; Hvas AM
Clin Case Rep; 2023 Sep; 11(9):e7859. PubMed ID: 37720715
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mTOR pathway expression in lymphatic malformation and related diseases.
Hori Y; Ozeki M; Hirose K; Matsuoka K; Matsui T; Kohara M; Tahara S; Toyosawa S; Fukao T; Morii E
Pathol Int; 2020 Jun; 70(6):323-329. PubMed ID: 32067331
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
15. Case report: Experience of a rare case of rebound of the Kasabach-Merritt phenomenon during sirolimus treatment in kaposiform hemangioendothelioma.
Wang L; Li J; Wu C; Song D; Liu Z; Niu Y; Zhou J; Guo L
Front Pediatr; 2022; 10():949950. PubMed ID: 35990005
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus.
Triana PJ; Dore M; Nuñez VC; Jimenez JG; Miguel MF; Díaz MG; Ricardo JN; Andres A; Lopez Santamaria M; Lopez-Gutierrez JC
European J Pediatr Surg Rep; 2017 Jan; 5(1):e32-e35. PubMed ID: 28761800
[No Abstract] [Full Text] [Related]
18. Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.
Ozeki M; Fujino A; Matsuoka K; Nosaka S; Kuroda T; Fukao T
Pediatr Blood Cancer; 2016 May; 63(5):832-8. PubMed ID: 26806875
[TBL] [Abstract][Full Text] [Related]
19. Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon: clinical characteristics and management.
Ji Y; Yang K; Chen S; Peng S; Lu G; Liu X
Cancer Manag Res; 2018; 10():3325-3331. PubMed ID: 30233248
[TBL] [Abstract][Full Text] [Related]
20. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma.
Peng S; Yang K; Xu Z; Chen S; Ji Y
J Paediatr Child Health; 2019 Sep; 55(9):1119-1124. PubMed ID: 30604513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
